VRCA
VRCA clinical trials: Verrica Pharmaceuticals Inc.
Every trial on ClinicalTrials.gov where Verrica Pharmaceuticals Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 10
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
VRCA on the catalyst calendar · VRCA registry changes
- Primary completion Nov 2027Sponsor estimatePhase 3NCT07457918Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)Verrica Pharmaceuticals Inc. · Common Warts (Verruca Vulgaris)RecruitingVRCALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 3NCT07246590Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)Verrica Pharmaceuticals Inc. · Common WartsActive, not recruitingVRCALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2027Sponsor estimatePhase 2NCT07881952Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)Verrica Pharmaceuticals Inc. · Common WartsNot yet recruitingVRCALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 3NCT07637734Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)Verrica Pharmaceuticals Inc. · Common WartsRecruitingVRCALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 15, 2024ActualPhase 2NCT05188729Open-Label Proof of Concept Study of VP-315 in Basal Cell CarcinomaVerrica Pharmaceuticals Inc. · Basal Cell CarcinomaCompletedVRCALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 21, 2020ActualPhase 2NCT03981822A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital WartsVerrica Pharmaceuticals Inc. · Condylomata AcuminataCompletedVRCALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 16, 2019ActualPhase 2NCT03487549Cantharidin and Occlusion in Verruca EpitheliumVerrica Pharmaceuticals Inc. · Common WartCompletedVRCALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 26, 2018ActualPhase 3NCT03377790Cantharidin Application in Molluscum Patients-1Verrica Pharmaceuticals Inc. · Molluscum ContagiosumCompletedVRCALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 26, 2018ActualPhase 3NCT03377803Cantharidin Application in Molluscum PatientsVerrica Pharmaceuticals Inc. · Molluscum ContagiosumCompletedVRCALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 25, 2018ActualPhase 2NCT03186378Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.Verrica Pharmaceuticals Inc. · Molluscum ContagiosumCompletedVRCALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner